Coronary angioplasty reduces the risk of spontaneous myocardial infarction in chronic stable patients.

Original title: Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease. Reference: Sripal Bangalore et al. Circulation. 2013;127:769-781

In the context of coronary angioplasty complications may arise, such as a periprocedural infarction. However, this event does not have the same clinical consequences compared to a spontaneous infarction. 

The goal of this meta analysis was to evaluate the incidence of the different types of myocardial infarction in patients with stable ischemic heart disease treated with PCI vs. optimal medical therapy (OMT). 8070 patients with stable chronic angina were included from 12 randomized studies that compared PCI vs. OMT. The average follow up was 5 years (between 1.5 to 10.2 years) and only a small number of patients in the angioplasty group received drug eluting stents.

PCI was associated to a significant 24% incidence reduction of spontaneous acute myocardial infarction (RR=0.76; 95% IC, 0.58–0.99) (type 1 infarction of the universal definition). ON the other hand, PCI was associated with a greater incidence of periprocedural infarction (type 4 infarction). If we take into account all infarction events together, we won´t see any differences between both strategies. (RR=0.96; 95% CI, 0.74–1.21). PCI was also associated with a reduction in all cause mortality rate, though it did not reach a significant statistical value. (RR=0.88; 95% CI, 0.75–1.03).

Conclusion: 

PCI, compared to OMT, in patients with stable ischemic heart disease, was associated with a significant reduction of spontaneous MI risk (type 1 of the universal definition) and a tendency to lower mortality rate, although it did not reach a significant statistical value.

Editorial comment: 

A lot has been written about the important difference in prognosis of spontaneous MI vs. periprocedural MI. The whole work revolves around this detail, since the tally simply tracks the number of infarction events, but the risk these events involve is very different. This difference in terms of risk can be perceived in the tendency to a lower mortality in patients treated with PCI.

SOLACI.ORG

More articles by this author

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...